Haisco Pharmaceutical Group: Announcement on Additional Provisional Proposals and Supplementary Notices for the 2023 Annual General Meeting of Shareholders
Haisco Pharmaceutical Group: Announcement on licensing and termination of the riluzole oral solution EXSERVAN project and preparation for impairment
Haisco Pharmaceutical Group: Announcement of Resolutions of the 14th Meeting of the Fifth Board of Directors
Haisco Pharmaceutical Group: Articles of Association (April 2024)
Haisco Pharmaceutical Group: Notice on the establishment of a subsidiary in Shannan City, Tibet Autonomous Region
Haisco Pharmaceutical Group: Announcement of Resolutions of the Sixth Meeting of the Fifth Board of Supervisors
Haisco Pharmaceutical Group: Notice on amending the “Articles of Association”
Haisco Pharmaceutical Group: Announcement on the pledge of some of the shares of the controlling shareholder
Haisco Pharmaceutical Group: Announcement on the cancellation of the pledge of some of the shares of the controlling shareholder
HiCisco: Annual Report on the Use of Funds Raised
HiCisco: Announcement of Supervisory Board Resolutions
HiCisco: Internal Control Self-Assessment Report
HiCisco: Announcement on Using Some Idle Funds Raised to Temporarily Replenish Liquidity
HiCisco: Announcement on the 2024 Remuneration Plan for Directors, Supervisors and Senior Management
HiCisco: 2023 Annual Audit Report
HiCisco: Independent Director's 2023 Annual Debriefing Report (YAN JONATHAN JUN)
HiCisco: Opinions of Huatai United Securities Co., Ltd. on the verification of Hisilicon Pharmaceuticals Group Co., Ltd.'s use of idle funds to entrust financial management
HiCisco: Independent Director's 2023 Debriefing Report (Le Jun)
HiCisco: Huatai United Securities Co., Ltd.'s verification opinion on the use of some idle funds raised by Hisilicon Pharmaceuticals Group Co., Ltd. to temporarily supplement working capital
HiCisco: Announcement on 2023 Profit Distribution Plan
No Data